211 related articles for article (PubMed ID: 33262944)
1. Multivariable Models Incorporating Multiparametric Magnetic Resonance Imaging Efficiently Predict Results of Prostate Biopsy and Reduce Unnecessary Biopsy.
Yu S; Hong G; Tao J; Shen Y; Liu J; Dong B; Fan Y; Li Z; Zhu A; Zhang X
Front Oncol; 2020; 10():575261. PubMed ID: 33262944
[TBL] [Abstract][Full Text] [Related]
2. Developing Strategy to Predict the Results of Prostate Multiparametric Magnetic Resonance Imaging and Reduce Unnecessary Multiparametric Magnetic Resonance Imaging Scan.
Liu J; Yu S; Dong B; Hong G; Tao J; Fan Y; Zhu Z; Wang Z; Zhang X
Front Oncol; 2021; 11():732027. PubMed ID: 34595118
[TBL] [Abstract][Full Text] [Related]
3. Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.
Liu J; Dong B; Qu W; Wang J; Xu Y; Yu S; Zhang X
Sci Rep; 2020 Mar; 10(1):5157. PubMed ID: 32198373
[TBL] [Abstract][Full Text] [Related]
4. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
5. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
6. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
7. Development and validation of a predictive model based on clinical and MpMRI findings to reduce additional systematic prostate biopsy.
Cheng X; Chen Y; Xu J; Cai D; Liu Z; Zeng H; Yao J; Song B
Insights Imaging; 2024 Jan; 15(1):3. PubMed ID: 38185753
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer.
Wagaskar VG; Levy M; Ratnani P; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Prasad S; Sobotka S; Haines K; Punnen S; Wiklund P; Tewari A
Eur Urol Open Sci; 2021 Jun; 28():9-16. PubMed ID: 34337520
[TBL] [Abstract][Full Text] [Related]
9. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
10. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
[TBL] [Abstract][Full Text] [Related]
11. Development and head-to-head comparison of machine-learning models to identify patients requiring prostate biopsy.
Yu S; Tao J; Dong B; Fan Y; Du H; Deng H; Cui J; Hong G; Zhang X
BMC Urol; 2021 May; 21(1):80. PubMed ID: 33993876
[TBL] [Abstract][Full Text] [Related]
12. Creating a novel multiparametric magnetic resonance imaging-based biopsy strategy for reducing unnecessary prostate biopsies: a retrospective cohort study.
Wang C; Shen D; Yuan L; Dong Q; Xu S; Liu Y; Xiao J
Quant Imaging Med Surg; 2024 Feb; 14(2):2021-2033. PubMed ID: 38415121
[TBL] [Abstract][Full Text] [Related]
13. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
14. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
[TBL] [Abstract][Full Text] [Related]
15. Combining Prostate-Specific Antigen Parameters With Prostate Imaging Reporting and Data System Score Version 2.0 to Improve Its Diagnostic Accuracy.
Baruah SK; Das N; Baruah SJ; Rajeev TP; Bagchi PK; Sharma D; Phukan M
World J Oncol; 2019 Dec; 10(6):218-225. PubMed ID: 31921377
[TBL] [Abstract][Full Text] [Related]
16. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract][Full Text] [Related]
17. The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations.
Ye C; Ho JN; Kim DH; Song SH; Kim H; Lee H; Jeong SJ; Hong SK; Byun SS; Ahn H; Hwang SI; Lee HJ; Lee S
Investig Clin Urol; 2022 Nov; 63(6):631-638. PubMed ID: 36347552
[TBL] [Abstract][Full Text] [Related]
18. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
19. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
Front Oncol; 2021; 11():740868. PubMed ID: 34589437
[TBL] [Abstract][Full Text] [Related]
20. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
